About InSphero
InSphero is a company based in Schlieren (Switzerland) founded in 2009. InSphero has raised $35.02 million across 10 funding rounds from investors including ZEISS, Zurcher Kantonalbank and European Union. InSphero has completed 1 acquisition, including PhenoVista. InSphero offers products and services including Akura Microplate Technology, Akura Organ-on-Chip Technology, and 3D InSight Liver Microtissues. InSphero operates in a competitive market with competitors including Newcells Biotech, Pandorum, Vivodyne, NextVivo and Adapsyn, among others.
- Headquarter Schlieren, Switzerland
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website insphero.com
- Social LinkedIn X Instagram YouTube
- Total Equity Funding$35.02M (USD)
in 10 rounds
- InvestorsZEISS
& 7 more
- Investments & Acquisitions
Products & Services of InSphero
InSphero offers a comprehensive portfolio of products and services, including Akura Microplate Technology, Akura Organ-on-Chip Technology, and 3D InSight Liver Microtissues.
Enables automated 3D cell culture for drug screening
Simulates human organs for advanced drug testing
Provides 3D liver models for toxicity and safety assessments
Apps and channels of InSphero
its YouTube channel InSphero has 143 subscribers and 30 videos.
Videos from InSphero
The most watched videos on InSphero's YouTube channel, InSphero (143 subscribers). Click a video to play it here.
More on InSphero.
Funding Insights of InSphero
InSphero has successfully raised a total of $35.02M across 10 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $35.02M
- Total Rounds 10
- First Round $121,832
(Jun 2009)
- Investors Count 8
All 10 funding rounds of InSphero with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2023 | – | Series D | – | ZEISS | – |
| Jun 2020 | $56,236 | Grant | – | – | |
| Jan 2020 | $56,095 | Grant | – | – | |
| Jun 2018 | $10M | Series C | – | Venturelab | |
| Jan 2018 | $578,873 | Grant | – | – | |
| Jan 2016 | – | Grant | – | – | |
| Jul 2015 | $21.14M | Series C | – | – | – |
| Jun 2013 | $2.17M | Series B | – | – | – |
| Aug 2010 | $1.72M | Series A | – | Redalpine | |
| Jun 2009 | $121,832 | Grant | – | – |
8 investors in total: 7 institutional and 1 angel.
Investors in InSphero
InSphero has secured backing from 8 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include ZEISS, Zurcher Kantonalbank and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Startup acceleration programs are operated across sectors to support growth. | – | venturelab.swiss | Schlieren, Switzerland | |
Early-stage investments are directed toward ICT and health tech startups. | – | redalpine.com | Zurich, Switzerland | |
University backed startup accelerator | – | venturekick.ch | Schlieren, Switzerland | |
Provider of diversified optics for microscopic instruments, medical imaging systems and more | 1846 | zeiss.com | Oberkochen, Germany | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Commercial banking services are provided across Switzerland by Zurcher Kantonalbank. | 1870 | zkb.ch | Zurich, Switzerland | |
JG Jürg Gysi | - | – | unknown_5702948d4f5e40c59 | - |
Investor details for InSphero
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of InSphero
22 people are tracked at InSphero (16 in leadership, 6 in team).
| Name | Role | Group |
|---|---|---|
Lisa Hoelting | Senior Scientist | Deputy VP Technologies & Platforms | Leadership |
Radina Kostadinova, PhD | Deputy VP Liver Disease Discovery, Senior Scientist | Leadership |
Madhu Lal Nag, MBS PhD | Chief Scientific Officer - Discovery | Leadership |
Nadia Carco | Executive Assistant to CEO & President | Leadership |
Mayank Chaubey, PhD.,MBA | Director Business Development (Europe, UK and APAC) | Leadership |
Arumugham (Ragoo) Raghunathan | Senior Director Business Development | Leadership |
Sue Grepper, PhD | West Coast Director of Business Development | Leadership |
Stina Näslund | Head of Human Resources | Leadership |
Marion Bavand | Head Quality Assurance | Leadership |
David Fluri | Head of Operations | Leadership |
Jan Lichtenberg | Chief Executive Officer and Board Member | Leadership |
Armin Wolf Prof, PhD | Chief Scientific Officer (CSO) | Leadership |
Paul Edgard Clémençon | Head Of Business Development | Leadership |
Burcak Yesildag | Vice President - Diabetes Research | Leadership |
Francisco Verdeguer | Vice President Liver Discovery | Leadership |
Wolfgang Moritz | Head of External Collaborations and IP | Leadership |
Daniel Zeisler | Operation Manager | Team |
Bärbel Ulmer | Business Development Manager Europe | Team |
Biljana Gemovic | Business Specialist | Team |
Christine Schwenk | Business Development Manager | Team |
2 more people are available in the full profile.
Complete people profiles for InSphero
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by InSphero
InSphero has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include PhenoVista.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
A CRO that provides phenotypic assay development and screening services. | phenovista.com | San Diego, United States | 2014 | May 2026 | •••• |
Complete acquisition details for InSphero
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of InSphero
4 dated milestones of InSphero across 17 years, from founding to its latest funding, stage changes and deals.
- Founded InSphero is founded.
- Funding First funding round of $122K.
- Funding Latest funding round, Series D,.
- Acquisition Acquires PhenoVista.
Competitors of InSphero
InSphero operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Newcells Biotech, Pandorum, Vivodyne, NextVivo and Adapsyn, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| newcellsbiotech.co.uk | 2014 | Newcastle Upon Tyne, United Kingdom | $14.43M | 22 | Induced pluripotent stem cell-derived organoid models are developed for research. | |
| pandorum.com | 2011 | Bengaluru, India | $36.82M | 28 | Regenerative medicine and 3D tissues are developed for therapeutic uses. | |
| vivodyne.com | 2021 | Philadelphia, United States | $117.69M | – | Developer of AI-based platform for lab-grown human tissues | |
| nextvivo.bio | 2021 | Palo Alto, United States | $7.9M | 8 | Immune-competent human-derived models are developed for drug discovery applications. | |
| adapsyn.com | 2016 | Hamilton, United States | – | – | Provider of computational tools for bacterial metabolomic and genomic data analysis | |
| parallel.bio | 2020 | Cambridge, United States | $25.43M | 6 | Limited information available | |
| vyantbio.com | 1999 | Cherry Hill, United States | $10.5M | 25 | Developer of drug discovery platform | |
| cellesce.com | 2013 | Cardiff, United Kingdom | – | 9 | Scalable processes for organoid expansion are developed. | |
| neucyte.com | 2015 | Sunnyvale, United States | $6.7M | 10 | Tools for neural cell production are developed using reprogramming technology. |
Detailed competitors of InSphero
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of InSphero
The website of InSphero (insphero.com) receives about 16.2K visits a month.
- Monthly visits16.2K
▲ 21.9% vs previous month
Websites whose visitors overlap most with InSphero. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
gelifesciences.com | gelifesciences.com | 100% | – | – | – |
stemcells.nih.gov | stemcells.nih.gov | 100% | – | – | – |
| trevigen.com | 100% | – | – | View details | |
| invitrogen.com | 100% | 5.2K | #3,688,642 | View details | |
| biotek.com | 100% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for InSphero
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Insphero
Complete news archive for InSphero
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to InSphero
10 companies that operate in the same segment as InSphero (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about InSphero
InSphero was founded in 2009.
InSphero is headquartered in Schlieren, Switzerland. It is registered at Schlieren, Zurich, Switzerland.
InSphero is a funded company, having raised a total of $35.02M across 10 funding rounds to date. The company's 1st funding round was a Grant of $121.83K, raised on Jun 2009.
InSphero was founded in 2009 in Schlieren, Switzerland, within the biotechnology sector. Organotypic 3D microtissues are produced for applications in biochemical compound screening and predictive drug testing. Services encompass compound toxicity testing, cell invasion assays, and interactions involving cells and extracellular matrices. Focus areas include metabolic diseases, oncology, and liver diseases, with offerings such as human prostate and mammary carcinoma, alongside rat liver microtissues.
InSphero's top competitors include Newcells Biotech, Vivodyne and Parallel Bio.
InSphero offers Akura Microplate Technology, Akura Organ-on-Chip Technology, and 3D InSight Liver Microtissues.
InSphero has made 1 acquisition, including PhenoVista.
InSphero has 8 investors. Key investors include ZEISS, Zurcher Kantonalbank, European Union, EIC Fund, and Jürg Gysi.